NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,202.94 +374.01 (+2.22%) CRUDE OIL
83.67 +0.31 (+0.37%) GOLD FUTURES
2,339.20 -2.90 (-0.12%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,652.42 +197.54 (+0.37%)
Viking Therapeutics, Inc. (VKTX)
After hours:
| Previous close | 63.85 |
| Open | 64.55 |
| Bid | 64.86 x 800 |
| Ask | 64.98 x 300 |
| Day's range | 63.51 - 67.58 |
| 52-week range | 8.28 - 99.41 |
| Volume | |
| Avg. volume | 6,455,517 |
| Market cap | 7.156B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.
- PR Newswire
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabol
- PR Newswire
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 7,441,650 shares of its common stock at a price to the public of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 970,650 additional shares of common stock. The gross proce
